Erythrocyte‐bound apolipoprotein B in atherosclerosis and mortality

Vries, Marijke A. de; Santen, Selvetta S. van; Klop, Boudewijn; Meulen, N. van der; Vliet, Marjolein van; Geijn, Gert‐Jan M. van de; Beek, Ellen M. van der Zwan-van; Birnie, Erwin; Liem, Anho; Herder, Wouter W. de; Cabezas, Manuel Castro

doi:10.1111/eci.12728

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, de Vries et al have shown that binding of apoB-containing lipoproteins to circulating erythrocytes, detected by flow cytometry, is associated with lower cardiovascular mortality. This inverse relationship between atherosclerosis and levels of erythrocyte-apoB binding can be considered as another means to use apoB as a biomarker [ 137 ].…”

Section: Biomarkers For Cvd: Ldl-c and Apobmentioning

confidence: 99%

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.

show abstract

Section: Biomarkers For Cvd: Ldl-c and Apobmentioning

confidence: 99%

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

show abstract

“…More specifically, apolipoprotein B (Apo-B) may be involved in the pathophysiology of AD and CVD; however, there is limited study on this potential involvement [ 30 ]. Atherosclerosis is known to be the most common contributor to CVD, and all the atherogenic lipoproteins have a single Apo-B molecule as their structural protein [ 31 ]. It has been shown that serum Apo-B, as one biomarker, is a strong predictor of CVD [ 32 ] and could play a role in regulating physical function in addition to indirectly impacting the lipid profile [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer’s Disease and Cardiovascular Diseases

Chun

García²,

Lu³

et al. 2021

Cells

View full text Add to dashboard Cite

Angiotensin-converting enzyme-1 (ACE1) and apolipoproteins (APOs) may play important roles in the development of Alzheimer’s disease (AD) and cardiovascular diseases (CVDs). This study aimed to examine the associations of AD, CVD, and endocrine-metabolic diseases (EMDs) with the levels of ACE1 and 9 APO proteins (ApoAI, ApoAII, ApoAIV, ApoB, ApoCI, ApoCIII, ApoD, ApoE, and ApoH). Non-Hispanic white individuals including 109 patients with AD, 356 mild cognitive impairment (MCI), 373 CVD, 198 EMD and controls were selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. Multivariable general linear model (GLM) was used to examine the associations. ApoE ε4 allele was associated with AD, as well as ApoAIV, ApoB and ApoE proteins, but not associated with CVD and EMD. Both AD and CVD were associated with levels of ACE1, ApoB, and ApoH proteins. AD, MCI and EMD were associated with levels of ACE1, ApoAII, and ApoE proteins. This is the first study to report associations of ACE1 and several APO proteins with AD, MCI, CVD and EMD, respectively, including upregulated and downregulated protein levels. In conclusion, as specific or shared biomarkers, the levels of ACE1 and APO proteins are implicated for AD, CVD, EMD and ApoE ε4 allele. Further studies are required for validation to establish reliable biomarkers for these health conditions.

show abstract

“…The results of their work are, among other things, meant to inform political decision making on science, technology and innovation. As an institute, it was involved in organizing public dialogues on new and existing technologies that (can) have a major impact on society, e.g., nanotechnology (Hanssen et al, 2008), synthetic biology (Rerimassie and Stemerding, 2014) and nuclear waste (De Vries et al, 2015). The ten lessons for the Dutch dialogue on HGGM were based on years of experience, a review of the debate on HGGM in the Netherlands so far and a systematic analysis of the social and ethical issues concerning HGGM.…”

Section: Lessons For a Public Dialoguementioning

confidence: 99%

How to fulfill the expert role in public dialogue: The Dutch dialogue on human germline genetic modification as a case

et al. 2022

View full text Add to dashboard Cite

Over the last decades science communication theory appears to have evolved at a much faster pace than science communication practice. Scientists seem willing to step into the public domain, but a genuine two-way interaction with the public is only rarely observed. We argue that part of this discrepancy between theory and practice may actually be caused by the lacking of a clear description of the modern expert role; the role a scientist should take in contemporary science communication. In this contribution we use an example of good practice—the Dutch dialogue on human germline genetic modification—to inform theory. We analyse guiding principles for the design and execution of this dialogue and observe expert behavior in three separate dialogue sessions. With the combined findings, we present a detailed description of the modern expert role in terms of three responsibilities, with for each responsibility three prompts for behavior. For the responsibility to share these are to select expert knowledge that is relevant to the goal; to present expert knowledge in a meaningful and accessible language; and to be cautious in sharing personal considerations. For the responsibility to listen and learn these are to consider interactions with members of the public as opportunities to learn; to be patient and supportive; and to assist in stimulating in-depth dialogue. For the responsibility to invest in relationships these are to assist in creating an ambiance of safety and relevance; to preserve trust; and to convey respect for every contribution and every point of view. Each behavioral prompt is further concretized with concomitant actions and practice examples as collected from observing experts in action. The implications for scientists engaging in contemporary science communication, as well as for science communication trainers, are discussed.

show abstract

Erythrocyte‐bound apolipoprotein B in atherosclerosis and mortality

Abstract: Low ery-apoB is associated with increased mortality and cardiovascular risk, especially in patients with a prior history of CVD. These subjects may benefit from more aggressive secondary prevention treatment.

Cited by 6 publications

References 23 publications

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer’s Disease and Cardiovascular Diseases

How to fulfill the expert role in public dialogue: The Dutch dialogue on human germline genetic modification as a case

Contact Info

Product

Resources

About